This study is in progress, not accepting new patients

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Description

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease, Crohn's Disease, Oral, Ozanimod, Moderately active, Severely active, RPC01, RPC01-3204, Administration of oral Ozanimod

For people ages 18-75

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com

Inclusion Criteria:

Is not in clinical response or clinical remission after completing 12 weeks in the Induction Studies
Experience relapse or who complete the Maintenance Study
Complete a study of ozanimod for Crohn's Disease and meet the criteria for participation

Exclusion Criteria:

Has any clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric, or other major systemic disease making implementation of the protocol or interpretation of the study difficult or that would put the subject at risk by participating in the study
Has suspected or diagnosed intra-abdominal or perianal abscess that has not been appropriately treated
Is receiving treatment with any of the following drugs or interventions: CYP2C8 inducers; Monoamine oxidase inhibitors

Other protocol-defined inclusion/exclusion criteria apply